Keyphrases
Respiratory Syncytial Virus Infection
100%
Pediatric Pulmonary
100%
Respiratory Syncytial Virus Bronchiolitis
42%
Respiratory Syncytial Virus
28%
Bronchiolitis
28%
Hospital Admission
14%
Most Vulnerable
14%
Malaria
14%
Clinical Practice Guidelines
14%
Viral
14%
Clinical Application
14%
Immune System
14%
Infection Control Procedures
14%
Asthma
14%
Poor Clinical Outcomes
14%
Clinical Benefit
14%
Immunoprophylaxis
14%
Lower Respiratory Tract Infection
14%
Repeated Infection
14%
Monoclonal Antibody
14%
Disease Burden
14%
Increased Mortality
14%
Neonatal Period
14%
Length of Hospital Stay
14%
Wheezing
14%
Ribavirin
14%
Respiratory Viruses
14%
Specific Treatment
14%
Clinical Syndromes
14%
Prophylactic Treatment
14%
Pneumonia
14%
Long Length
14%
Virus Diseases
14%
Causes of Mortality
14%
Otitis Media
14%
Upper Respiratory Tract Infection
14%
Current Management
14%
Successful Treatment
14%
Vulnerable children
14%
Drug Toxicity
14%
Oxygen Supplementation
14%
Nosocomial Transmission
14%
Hospitalization Risk
14%
Palivizumab
14%
High-risk Infants
14%
Mandatory Vaccines
14%
Treatment Agent
14%
Isolation Control
14%
Commercial Drugs
14%
Medicine and Dentistry
Pediatrics
100%
Respiratory Syncytial Virus Infection
100%
Human Respiratory Syncytial Virus
71%
Bronchiolitis
71%
Diseases
28%
Infection
14%
Supplementation
14%
Respiratory Disease
14%
Immunoprophylaxis
14%
Monoclonal Antibody
14%
Newborn Period
14%
Asthma
14%
Lower Respiratory Tract
14%
Clinical Syndrome
14%
Disease Burden
14%
Wheeze
14%
Infection Control
14%
Otitis Media
14%
Clinical Guideline
14%
Drug Toxicity
14%
Upper Respiratory Tract Infection
14%
Ribavirin
14%
Palivizumab
14%
High Risk Infant
14%
Virus
14%
Immune System
14%
Pharmacology, Toxicology and Pharmaceutical Science
Respiratory Syncytial Virus Infection
100%
Human Respiratory Syncytial Virus
71%
Bronchiolitis
71%
Diseases
42%
Infection
28%
Asthma
14%
Respiratory Tract Disease
14%
Syndrome
14%
Monoclonal Antibody
14%
Wheezing
14%
Ribavirin
14%
Drug Toxicity
14%
Otitis Media
14%
Upper Respiratory Tract Infection
14%
Respiratory Virus
14%
Palivizumab
14%
Immunology and Microbiology
Respiratory Syncytial Virus Infection
100%
Human Respiratory Syncytial Virus
71%
Bronchiolitis
71%
Lower Respiratory Tract
14%
Disease Burden
14%
Monoclonal Antibody
14%
Upper Respiratory Tract
14%
Asthma
14%
Ribavirin
14%
Respiratory Virus
14%
Newborn Period
14%
Otitis Media
14%
Palivizumab
14%
Drug Toxicity
14%
Immune System
14%